Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Novartis AG (NVS) Price & Performance

JPMorgan Nasdaq Equity Premium Income ETFTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

JPMorgan Nasdaq Equity Premium Income ETF vs Novartis AG — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.99, while Novartis AG trades at $152.76 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.

JEPQNVS
Sector
Income / Options OverlayHealth
52-Week High
$61.46$168.62
52-Week Low
$53.77$119.31
Market Cap
$295.37B
Enterprise Value
$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ trades at $60.01, up 0.55% today, with a bullish technical signal from moving averages. The ETF focuses on Nasdaq-100 exposure with an options income strategy, generating monthly distributions. Recent news highlights its role in retirement income portfolios but notes tax implications for distributions. Key support sits at $59, with resistance at $60.

The outlook remains positive for income-seeking investors, supported by institutional buying and media coverage. Risks include tax treatment of distributions and market volatility affecting the underlying Nasdaq holdings. Analyst sentiment is mixed due to high RSI levels suggesting potential overbought conditions near-term.

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About JPMorgan Nasdaq Equity Premium Income ETF

JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.

Read more on JEPQ

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS